Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States

Vaccine
Desmond CurranBarbara P Yawn

Abstract

In the United States, herpes zoster (HZ) and related complications are estimated to result in approximately $1.3 billion in medical care costs and $1.7 billion in indirect costs annually. In this study, we compared the cost-effectiveness of a new Adjuvanted Recombinant Zoster Vaccine (RZV), containing recombinant varicella-zoster virus glycoprotein E and the AS01B Adjuvant System, versus No Vaccine, as well as versus the live attenuated HZ vaccine (Zoster Vaccine Live (ZVL)) in subjects aged 60+ years of age (YOA) and other age cohorts aged 50+ YOA. A multi-cohort Markov model was developed which follows 1 million individuals over their remaining lifetimes from the year of vaccination with annual cycle lengths. Second dose compliance for RZV was assumed to be 69%. Efficacy and waning parameters were derived from clinical trials for both vaccines. Epidemiological parameters, costs and utility model inputs were derived from US-specific population-based data. Costs and outcomes were discounted at 3% per year. Deterministic and probabilistic sensitivity analysis, along with scenario and threshold analysis were carried out to explore the overall uncertainty in the model. The model estimated that, compared to No Vaccine against HZ, R...Continue Reading

Citations

Nov 7, 2018·JAMA Internal Medicine·Phuc Le, Michael B Rothberg
Nov 7, 2018·JAMA Internal Medicine·Desmond CurranPhilip Buck
Jun 13, 2020·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Kenneth E SchmaderDesmond Curran
Apr 1, 2019·Dermatology and Therapy·Makoto ShiragamiDaisuke Watanabe
Jun 30, 2019·Applied Health Economics and Health Policy·Ashleigh McGirrDesmond Curran
Aug 24, 2019·Human Vaccines & Immunotherapeutics·Antonio VolpiElisabetta Franco
Aug 8, 2020·Human Vaccines & Immunotherapeutics·Sandra E TalbirdCosmina S Hogea
Oct 13, 2020·Journal of Managed Care & Specialty Pharmacy·Brandon J PattersonHung-Fu Tseng
Jan 7, 2021·Journal of Market Access & Health Policy·Mohamed Neine, Desmond Curran
Feb 25, 2021·BMJ Open·James F MbintaColin R Simpson
Jul 2, 2021·Mayo Clinic Proceedings. Innovations, Quality & Outcomes·Brandon J PattersonJeffrey J Stoddard
Dec 8, 2021·Infectious Diseases and Therapy·Desmond CurranBarbara P Yawn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.